Teva Pharmaceutical Industries Limited (TEVA) Inventory Turnover Ratio, from third quarter 2026 to third quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)
 

Teva Pharmaceutical Industries Limited Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Teva Pharmaceutical Industries Limited's inventory turnover ratio, the ratio that measures Teva Pharmaceutical Industries Limited's ability to manage its supply chain, sequentially decreased to 3.16 in the third quarter 2026, which does not come as a surprise, as the Teva Pharmaceutical Industries Limited continue to experience headwinds, which also impact its supply chain. Teva Pharmaceutical Industries Limited's average inventory processing period in the Sep 30 2026 quarter, has increased to 116 days, from 100 days, in the Jun 30 2026 quarter.

Within Healthcare sector 106 other companies have achieved higher inventory turnover ratio. While Inventory turnover ratio total ranking has improved so far during the III Quarter 2026, to 952, from total ranking in the second quarter 2026 at 1103.

TEVA Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Teva Pharmaceutical Industries Limited Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TEVA Inventory Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Inventory Growth 56.54 % 52.94 % -2.48 % 6.79 % -12.4 %
Y / Y Cost of Sales Growth -10.16 % -4.1 % -0.15 % -2.56 % -0.32 %
Inventory Turnover Ratio (TTM) 3.16 3.66 4.22 4.2 4.29
TEVA's Total Ranking # 952 # 1103 # 966 # 979 # 981
Average inventory processing period 116 100 87 87 85
Seq. Inventory Growth -1.49 % 74.3 % -2.94 % -6.07 % -3.75 %
Seq. Cost of Sales Growth -1.71 % -1.09 % -2.19 % -5.51 % 4.92 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 107
Overall Market # 952

Inventory Turnover Ratio Statistics
High Average Low
4.64 3.83 2.21
(Sep 30 2014)   (Dec 31 2009)



TEVA Company Profile >> Back to TEVA Efficiency Comparisons >> Compare TEVA Inventory Turnover Ratio to its Competitors

Financial Statements
Teva Pharmaceutical Industries Limited's Inventories $ 3,173 Millions Visit TEVA's Balance sheet
Teva Pharmaceutical Industries Limited's Cost of Revenues TTM $ 8,011 Millions Visit TEVA's Income Statement
What are TEVA's Sales? Visit TEVA's Sales by Segment

Other Inventory Turnover Ratios
Teva Pharmaceutical Industries Limited's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
TEVA's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for TEVA's Competitors
Inventory Turnover Ratio for TEVA's Suppliers
Inventory Turnover Ratio for TEVA's Customers

You may also want to know
TEVA's Sales Growth Rates TEVA's Pe Price to earnings ratio TEVA's Receivables Turnover Ratio TEVA's Stock Quote
TEVA's Net Income Growth Rates TEVA's Ps Price to Sales ratio TEVA's Sales per Employee TEVA's Asset Turnover Ratio
TEVA's Net Margin TEVA's Pb Price to Book ratio TEVA's Financial Strength Ratios TEVA's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Sep 30 2026 Inventories at quarter ending Sep 30 2026
Caredx Inc   6.42 $ 111.106  Millions$ 17  Millions
Bristol myers Squibb Company  5.65 $ 15,389.000  Millions$ 2,722  Millions
Avantor Inc   5.48 $ 4,539.200  Millions$ 828  Millions
Tactile Systems Technology Inc   5.25 $ 82.718  Millions$ 16  Millions
Integer Holdings Corporation  4.98 $ 1,376.268  Millions$ 276  Millions
Ge Healthcare Technologies Inc   4.69 $ 11,372.000  Millions$ 2,425  Millions
West Pharmaceutical Services Inc   4.69 $ 2,120.200  Millions$ 452  Millions
Idexx Laboratories Inc  4.52 $ 1,743.379  Millions$ 386  Millions
Medinotec Inc   4.28 $ 5.143  Millions$ 1  Millions
3m Company  4.02 $ 15,267.000  Millions$ 3,801  Millions
Novocure Limited  3.98 $ 166.721  Millions$ 42  Millions
Incyte Corporation  3.79 $ 439.399  Millions$ 116  Millions
Baxter International Inc   3.57 $ 8,117.000  Millions$ 2,277  Millions
Bausch Health Companies Inc   3.54 $ 4,518.000  Millions$ 1,276  Millions
Exelixis Inc   3.49 $ 93.324  Millions$ 27  Millions
Gilead Sciences Inc   3.30 $ 6,219.000  Millions$ 1,884  Millions
Mimedx Group Inc   2.98 $ 70.562  Millions$ 24  Millions
Ligand Pharmaceuticals Incorporated  2.93 $ 34.495  Millions$ 12  Millions
Neogen Corporation  2.89 $ 464.774  Millions$ 161  Millions
Biomerica Inc   2.65 $ 4.297  Millions$ 2  Millions
Dexcom Inc   2.65 $ 1,867.500  Millions$ 705  Millions
Angiodynamics Inc   2.50 $ 142.709  Millions$ 57  Millions
Pro dex Inc   2.45 $ 53.753  Millions$ 22  Millions
Illumina Inc   2.36 $ 1,458.000  Millions$ 618  Millions
Resmed Inc   2.33 $ 2,214.675  Millions$ 952  Millions
Beta Bionics Inc   2.31 $ 53.285  Millions$ 23  Millions
Merit Medical Systems Inc  2.25 $ 817.001  Millions$ 363  Millions
Bioventus Inc   2.24 $ 183.856  Millions$ 82  Millions
Johnson and Johnson  2.17 $ 32,222.000  Millions$ 14,824  Millions
Glaukos Corp  2.13 $ 131.180  Millions$ 62  Millions

Date modified: 2026-11-04T10:24:57+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.